Format

Send to

Choose Destination
Mol Cells. 2015 Aug;38(8):669-76. doi: 10.14348/molcells.2015.0175. Epub 2015 Jul 21.

Exploiting the Fanconi Anemia Pathway for Targeted Anti-Cancer Therapy.

Author information

1
Department of Pharmacological Sciences, Stony Brook University, New York 11794, USA.

Abstract

Genome instability, primarily caused by faulty DNA repair mechanisms, drives tumorigenesis. Therapeutic interventions that exploit deregulated DNA repair in cancer have made considerable progress by targeting tumor-specific alterations of DNA repair factors, which either induces synthetic lethality or augments the efficacy of conventional chemotherapy and radiotherapy. The study of Fanconi anemia (FA), a rare inherited blood disorder and cancer predisposition syndrome, has been instrumental in understanding the extent to which DNA repair defects contribute to tumorigenesis. The FA pathway functions to resolve blocked replication forks in response to DNA interstrand cross-links (ICLs), and accumulating knowledge of its activation by the ubiquitin-mediated signaling pathway has provided promising therapeutic opportunities for cancer treatment. Here, we discuss recent advances in our understanding of FA pathway regulation and its potential application for designing tailored therapeutics that take advantage of deregulated DNA ICL repair in cancer.

KEYWORDS:

DNA interstrand cross-link; DNA repair; Fanconi anemia; cancer therapeutics; ubiquitin signaling

PMID:
26194820
PMCID:
PMC4546938
DOI:
10.14348/molcells.2015.0175
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Publishing M2Community Icon for PubMed Central
Loading ...
Support Center